|
The
use of antipsychotic agents in children and adolescents has
increased substantially over the past decade. There is
increased public scrutiny, controversy and debate regarding
the increasing use of the antipsychotic agents in children
and the lack of data on long-term effects.
The long-term efficacy and safety of
these agents in the pediatric population has not been
well-established for any given clinical indication.
|
|
For these reasons, the State of Maryland Medicaid
Pharmacy Program (MMPP) is launching a new program – The
Peer Review Program for Mental Health Drugs.
The program will start in October
2011 and will initially address the use of
antipsychotics in Medicaid patients under five years of
age.
In partnership with the Mental
Hygiene Administration (MHA) and the University of
Maryland (UMD) Division of Child and Adolescent
Psychiatry and School of Pharmacy, the program’s goal is
to ensure that members of this vulnerable population
receive optimal treatment in concert with appropriate
non-pharmacologic measures in the safest manner
possible.
The MMPP and the Mental Hygiene Administration hosted a Webinar to discuss the Peer Review Program and answer questions regarding this program on Thursday September 15, 2011 from 8:30 – 9:30 AM.
To download a recording of this webinar,
click here. *
To view the streaming recording of the webinar,
click here. *
To view the powerpoint used during the webinar without audio,
click here.
*It is necessary for you to have WebEx ARF Player installed in your computer in order to download or view Webinar recordings.
are PDF. Download
Adobe Acrobat Reader for viewing .pdf files
